Cancer has a high mortality rate across the globe, and tissue biopsy remains the gold
standard for tumor diagnosis due to its high level of laboratory standardization, good …

Background The utility of liquid biopsies is well documented in several extracranial and
intracranial (brain/leptomeningeal metastases, gliomas) tumors. Methods The RANO …

Recurrence risks of cancer patient can change during treatment as a result of treatment-
related tumor evolution. However, biomarkers that can monitor these changes are lacking …

Accurate intraoperative differentiation of primary central nervous system lymphoma (PCNSL)
remains pivotal in guiding neurosurgical decisions. However, distinguishing PCNSL from …

Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-
based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which …

Polatuzumab vedotin (Pola-V) is an antibody–drug conjugate directed to the CD79B subunit
of the B-cell receptor (BCR). When combined with conventional immunochemotherapy, Pola …

State-of-the-art response assessment of central nervous system lymphoma (CNSL) by
magnetic resonance imaging is challenging and an insufficient predictor of treatment …

Early diagnosis is crucial for the successful treatment of primary CNS lymphoma (PCNSL), a
rapidly progressing tumour. Suspicion raised on brain MRI must be confirmed by a …

Diagnosis of primary central nervous system lymphoma (PCNSL) is challenging, and
although brain biopsy remains the gold standard, cerebrospinal fluid (CSF) constitutes a …

Diffuse large B-cell lymphoma (DLBCL) encompasses a diverse spectrum of aggressive B-
cell lymphomas with remarkable genetic heterogeneity and myriad clinical presentations …